Loading

VASTHERA Co., Ltd

June 16, 2025
Company Presentation
Cardiovascular
Vasthera Co., Ltd. is a Korea-based pre-clinical stage pharmaceutical company pioneering first-in-class drugs for chronic inflammatory diseases, such as cardiovascular, cancer, eye, and neurodegenerative diseases, through innovative platforms, 'Redoxizyme' and 'ATGen,' which generate small molecules that target redox and autophagy (ATG) signaling pathways critical for the onset and pathogenesis of these diseases.
VASTHERA Co., Ltd
Company HQ City: Seoul
Company HQ Country: Korea, Republic of
Year Founded: 2018
Lead Product in Development: VTB-10 for pulmonary arterial hypertension will enter phase 1 trials this year.

CEO

Sang Won Kang, PhD

Year Founded

2018

Development Phase of Lead Product

Pre-Clinical

Number of Unlicensed Products Looking for Licensing

3

When you expect your next catalyst update?

The company is currently undergoing due diligence for a partnership (L/O) agreement, with strong prospects for closing the deal by the end of this year. This partnership could significantly enhance the company’s strategic position and drive future growth. Additionally, the Phase 1 clinical trial for VTB-10 is progressing well, with results expected by June next year. Positive data from this trial could serve as a major value inflection point, paving the way for further clinical development and potential commercialization.

What is your next catalyst (value inflection) update?

December 2025

Website

http://vasthera.com/
Primary Speaker
Kyuwon Cho
Kyuwon Cho, PhD
Director of Business Development
VASTHERA Co., Ltd

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS